According to @gdb, a custom LLM named gpt-4b micro designed novel Yamanaka factor variants that achieved a 50x increase in reprogramming efficiency in vitro versus standard OSKM proteins; source: Greg Brockman on X, Aug 22, 2025, https://twitter.com/gdb/status/1958928877415510134. The post attributes the advance to LLM-driven protein design and provides no peer-reviewed data, methods, in vivo results, or commercialization details, and it does not reference cryptocurrencies or blockchain; source: Greg Brockman on X, Aug 22, 2025, https://twitter.com/gdb/status/1958928877415510134. For trading context, the announcement is a headline-only indicator of AI-biology convergence without quantifiable read-through to crypto markets from the source text; source: Greg Brockman on X, Aug 22, 2025, https://twitter.com/gdb/status/1958928877415510134.